1. In clinical studies, the median time of onset of at least 1-point improvement, in line severity was 3 days. Mueller DS, et al. Efficacy and Safety of Letibotulinumtoxin A in the Treatment of Glabellar Lines: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study. Aesthet Surg J. 2022;42(6):677-688.
2. In clinical studies, the duration of treatment effect, defined as the time frame in which statistically significant difference in responder rate exists between the Letybo® group and the placebo group, was 16 weeks. Responder rate here is defined as the proportion of subjects with a ≥1-po int improvement on the Facial Wrinkle Scale at maximum frown relative to baseline, based on both the investigator’s and the subject’s assessments. Mueller DS, et al. 2022.
3. Data on file: Total accumulated global sales. 2023.
4,6. Mueller DS, Prins V, Adel glass J, et.al. Efficacy and Safety of LetibotulinumtoxinA in the Treatment of Glaellar Lines: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study. Aesthet Surgj. 2022;42(6):677-688.
5. Results from clinical trials. Based on adults’ assessment compared to actual age after treatment at week 4 (mean change of -2.4 years vs. -0.2 years for Letybo® and placebo, respectively). Improvement was measured by the Face-Q Appraisal of Lines Between Eyebrows Scale and the Face-Q Age Appraisal Visual Analog Scale (VAS) as absolute change from baseline. Cox SE, et al. 2022.
